Advanced search
Publication Cover
Aging Health Volume 5, 2009 - Issue 4
Journal homepage
36
Views
0
CrossRef citations to date
0
Altmetric
Review

Current Advancements in the Management of Giant Cell Arteritis

Parasar Ghosha Department of Rheumatology, Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, Essex, SS0 0RY, UK. [email protected]View further author information
,
Frances A Borgb Department of Rheumatology, Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, Essex, SS0 0RY, UK. [email protected]View further author information
&
Bhaskar Dasguptac Department of Rheumatology, Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, Essex, SS0 0RY, UK. [email protected]Correspondence[email protected]
View further author information
Pages 519-534 | Published online: 21 Jul 2009

Bibliography

  • Machado EB , MichetCJ, BallardDJet al.: Trends in incidence and clinical presentation of temporal arteritis in olmsted county, minnesota, 1950–1985.Arthritis Rheum.31, 745–749(1988).
  • Penn H , DasguptaB: Giant cell arteritis.Autoimmun. Rev.2, 199–203(2003).
  • Gonzalez-Gay MA , Miranda-FilloyJA, Lopez-DiazMJet al.: Giant cell arteritis in northwestern spain: a 25-year epidemiologic study.Medicine (Baltimore)86, 61–68(2007).
  • Smeeth L , CookC, HallAJ: Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the united kingdom, 1990–2001.Ann. Rheum. Dis.65, 1093–1098(2006).
  • Kumar VA , FaustoKA: In: Robbin and cortan pathologic basis of disease (7th Edition). Elsevier Saunders, Philadelphia, PA, USA (2005).
  • Gonzalez-Gay MA , AmoliMM, Garcia-PorruaC, OllierWE: Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.Semin. Arthritis Rheum.33, 38–48(2003).
  • Salvarani C , BoiardiL, MantovaniVet al.: HLA-drb1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity.Ann. Rheum. Dis.58, 303–308(1999).
  • Hernandez-Rodriguez J , Garcia-MartinezA, CasademontJet al.: A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.Arthritis Rheum.47, 29–35(2002).
  • Mattey DL , HajeerAH, DababnehAet al.: Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms.Arthritis Rheum.43, 1749–1755(2000).
  • Gonzalez-Gay MA , HajeerAH, DababnehAet al.: Interferon-g gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica.Clin. Exp. Rheumatol.22, S18–S20 (2004).
  • Rueda B , Lopez-NevotMA, Lopez-DiazMJet al.: A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis.J. Rheumatol.32, 1737–1741(2005).
  • Segarra M , Garcia-MartinezA, SanchezMet al.: Gelatinase expression and proteolytic activity in giant-cell arteritis.Ann. Rheum. Dis.66, 1429–1435(2007).
  • Rueda B , Miranda-FilloyJA, MartinJ, Gonzalez-GayMA: Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis.J. Rheumatol.35, 850–854(2008).
  • Salvarani C , GabrielSE, O‘FallonWM, HunderGG: The incidence of giant cell arteritis in olmsted county, minnesota: Apparent fluctuations in a cyclic pattern.Ann. Intern Med.123, 192–194(1995).
  • Narvaez J , ClavagueraMT, Nolla-SoleJM, Valverde-GarciaJ, Roig-EscofetD: Lack of association between infection and onset of polymyalgia rheumatica.J. Rheumatol.27, 953–957(2000).
  • Wagner AD , GerardHC, FresemannTet al.: Detection of chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells.Arthritis Rheum.43, 1543–1551(2000).
  • Lopez-Hoyos M , AlvarezL, Ruiz Soto M et al.: Serum levels of antibodies to chlamydia pneumoniae and human hsp60 in giant cell arteritis patients. Clin. Exp. Rheumatol.26, 1107–1110(2008).
  • Brack A , GeislerA, Martinez-TaboadaVMet al.: Giant cell vasculitis is a T cell-dependent disease.Mol. Med.3, 530–543(1997).
  • Weyand CM , SchonbergerJ, OppitzUet al.: Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes.J. Exp. Med.179, 951–960(1994).
  • Ma-Krupa W , JeonMS, SpoerlSet al.: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis.J. Exp. Med.199, 173–183(2004).
  • Oriss TB , OstroukhovaM, Seguin-DevauxCet al.: Dynamics of dendritic cell phenotype and interactions with CD4+ T cells in airway inflammation and tolerance.J. Immunol.174, 854–863(2005).
  • Lau AH , ThomsonAW: Dendritic cells and immune regulation in the liver.Gut52, 307–314(2003).
  • Pryshchep O , Ma-KrupaW, YoungeBR, GoronzyJJ, WeyandCM: Vessel-specific Toll-like receptor profiles in human medium and large arteries.Circulation118, 1276–1284(2008).
  • Otero C , EiselePS, SchaeubleK, GroettrupM, LeglerDF: Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis.J. Cell Sci.121, 2759–2767(2008).
  • Krupa WM , DewanM, JeonMSet al.: Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis.Am. J. Pathol.161, 1815–1823(2002).
  • Cid MC , HoffmanMP, Hernandez-RodriguezJet al.: Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis.Rheumatology (Oxford)45, 1356–1363(2006).
  • Ross R : Cellular and molecular studies of atherogenesis.Atherosclerosis131, S3–S4 (1997).
  • Salvarani C , MacchioniPL, TartoniPLet al.: Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy.Clin. Exp. Rheumatol.5, 205–215(1987).
  • Hunder GG , BlochDA, MichelBAet al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.Arthritis Rheum.33, 1122–1128(1990).
  • Gonzalez-Gay MA , Garcia-PorruaC, Amor-DoradoJC, LlorcaJ: Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population.Arthritis Rheum.51, 652–655(2004).
  • Mukhtyar C , GuillevinL, CidMCet al.: Eular recommendations for the management of large vessel vasculitis.Ann. Rheum. Dis.68, 318–323(2009).
  • Gonzalez-Gay MA , Garcia-PorruaC, LlorcaJet al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients.Medicine (Baltimore)79, 283–292(2000).
  • Loddenkemper T , SharmaP, KatzanI, PlantGT: Risk factors for early visual deterioration in temporal arteritis.J. Neurol. Neurosurg. Psychiatry78, 1255–1259(2007).
  • Salvarani C , CiminoL, MacchioniPet al.: Risk factors for visual loss in an italian population-based cohort of patients with giant cell arteritis.Arthritis Rheum.53, 293–297(2005).
  • Nesher G , BerkunY, MatesMet al.: Risk factors for cranial ischemic complications in giant cell arteritis.Medicine (Baltimore)83, 114–122(2004).
  • Danesh-Meyer H , SavinoPJ, GambleGG: Poor prognosis of visual outcome after visual loss from giant cell arteritis.Ophthalmology112, 1098–1103(2005).
  • Makkuni D , BharadwajA, WolfeK, PayneS, HutchingsA, DasguptaB: Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis?Rheumatology (Oxford)47, 488–490(2008).
  • Achkar AA , LieJT, HunderGG, O‘FallonWM, GabrielSE: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?Ann. Intern Med.120, 987–992(1994).
  • Smetana GW , ShmerlingRH: Does this patient have temporal arteritis?JAMA287, 92–101(2002).
  • Gonzalez-Gay MA , Garcia-PorruaC, LlorcaJ, Gonzalez-LouzaoC, Rodriguez-LedoP: Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy.Semin. Arthritis Rheum.30, 249–256(2001).
  • Salvarani C , CasaliB, FarnettiEet al.: PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis.Arthritis Rheum.56, 3502–3508(2007).
  • Garcia-Martinez A , Hernandez-RodriguezJ, ArguisPet al.: Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.Arthritis Rheum.59, 422–430(2008).
  • Agard C , BarrierJH, DupasBet al.: Aortic involvement in recent-onset giant cell (temporal) arteritis: a case–control prospective study using helical aortic computed tomodensitometric scan.Arthritis Rheum.59, 670–676(2008).
  • Nuenninghoff DM , HunderGG, ChristiansonTJ, McClellandRL, MattesonEL: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.Arthritis Rheum.48, 3522–3531(2003).
  • Mahr A , SabaM, KambouchnerMet al.: Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?Ann. Rheum. Dis.65, 826–828(2006).
  • Boyev LR , MillerNR, GreenWR: Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis.Am. J. Ophthalmol.128, 211–215(1999).
  • Danesh-Meyer HV , SavinoPJ, EagleRC Jr, Kubis KC, Sergott RC: Low diagnostic yield with second biopsies in suspected giant cell arteritis. J. Neuroophthalmol.20, 213–215(2000).
  • Chakrabarty A , FranksAJ: Temporal artery biopsy: is there any value in examining biopsies at multiple levels?J. Clin. Pathol.53, 131–136(2000).
  • Ray-Chaudhuri N , KineDA, TijaniSOet al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis.Br. J. Ophthalmol.86, 530–532(2002).
  • Schmidt WA , KraftHE, VorpahlK, VolkerL, Gromnica-IhleEJ: Color duplex ultrasonography in the diagnosis of temporal arteritis.N. Engl. J. Med.337, 1336–1342(1997).
  • Murgatroyd H , NimmoM, EvansA, MacEwenC: The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings.Eye17, 415–419(2003).
  • Karassa FB , MatsagasMI, SchmidtWA, IoannidisJP: Meta-analysis: test performance of ultrasonography for giant-cell arteritis.Ann. Intern Med.142, 359–369(2005).
  • Turlakow A , YeungHW, PuiJet al.: Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis.Arch. Intern Med.161, 1003–1007(2001).
  • Blockmans D , de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H: Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum.55, 131–137(2006).
  • Hautzel H , SanderO, HeinzelA, SchneiderM, MullerHW: Assessment of large-vessel involvement in giant cell arteritis with 18F-fdg pet: introducing an roc- analysis-based cutoff ratio.J. Nucl. Med.49, 1107–1113(2008).
  • Blockmans D , CoudyzerW, VanderschuerenSet al.: Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis.Rheumatology (Oxford)47, 1179–1184(2008).
  • Narvaez J , NarvaezJA, NollaJM, SirventE, ReinaD, ValverdeJ: Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis.Rheumatology (Oxford)44, 479–483(2005).
  • Bley TA , UhlM, CarewJet al.: Diagnostic value of high-resolution mr imaging in giant cell arteritis.AJNR Am. J. Neuroradiol.28, 1722–1727(2007).
  • Bley TA , MarklM, SchelpMet al.: Mural inflammatory hyperenhancement in mri of giant cell (temporal) arteritis resolves under corticosteroid treatment.Rheumatology (Oxford)47, 65–67(2008).
  • Borg F , EzeoneyejiA, WongW, RiazI, GordonT, DasguptaB: Giant cell arteritis: an audit of early recognition and management.Rheumatology (Oxford)48, 43 (2009).
  • Tarkkanen A : Giant cell arteritis and the ophthalmologist.Acta Ophthalmol. Scand.80, 353–354(2002).
  • Hayreh SS , ZimmermanB: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy.Ophthalmology110, 1204–1215(2003).
  • Proven A , GabrielSE, OrcesC, O‘FallonWM, HunderGG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.Arthritis Rheum.49, 703–708(2003).
  • Mazlumzadeh M , HunderGG, EasleyKAet al.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.Arthritis Rheum.54, 3310–3318(2006).
  • Chan CC , PaineM, O‘DayJ: Steroid management in giant cell arteritis.Br. J. Ophthalmol.85, 1061–1064(2001).
  • Foroozan R , DeramoVA, BuonoLMet al.: Recovery of visual function in patients with biopsy-proven giant cell arteritis.Ophthalmology110, 539–542(2003).
  • Chevalet P , BarrierJH, PottierPet al.: A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients.J. Rheumatol.27, 1484–1491(2000).
  • Nesher G , BerkunY, MatesMet al.: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.Arthritis Rheum.50, 1332–1337(2004).
  • Weyand CM , KaiserM, YangH, YoungeB, GoronzyJJ: Therapeutic effects of acetylsalicylic acid in giant cell arteritis.Arthritis Rheum.46, 457–466(2002).
  • Narvaez J , BernadB, Gomez-VaqueroCet al.: Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis.Clin. Exp. Rheumatol.26, S57–S62 (2008).
  • Gonzale-Gayz MA , PineiroA, Gomez-GigireyAet al.: Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis.Medicine (Baltimore)83, 342–347(2004).
  • Berger CT , WolbersM, MeyerP, DaikelerT, HessC: High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.Rheumatology (Oxford)48, 258–261(2009).
  • Salvarani C , Della Bella C, Cimino L et al.: Risk factors for severe cranial ischaemic events in an italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford)48, 250–253(2009).
  • Jover JA , Hernandez-GarciaC, MoradoIC, VargasE, BanaresA, Fernandez-GutierrezB: Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial.Ann. Intern Med.134, 106–114(2001).
  • Spiera RF , MitnickHJ, KupersmithMet al.: A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (gca).Clin. Exp. Rheumatol.19, 495–501(2001).
  • Hoffman GS , CidMC, HellmannDBet al.: A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.Arthritis Rheum.46, 1309–1318(2002).
  • Mahr AD , JoverJA, SpieraRFet al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.Arthritis Rheum.56, 2789–2797(2007).
  • De Silva M , HazlemanBL: Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.Ann. Rheum. Dis.45, 136–138(1986).
  • Dharmapaliah C , BorgF, DasguptaB: Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica amd giant cell arteritis: a case series.Rheumatology (Oxford)48, 42 (2009).
  • Cantini F , NiccoliL, SalvaraniC, PadulaA, OlivieriI: Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.Arthritis Rheum.44, 2933–2935(2001).
  • Tan AL , HoldsworthJ, PeaseC, EmeryP, McGonagleD: Successful treatment of resistant giant cell arteritis with etanercept.Ann. Rheum. Dis.62, 373–374(2003).
  • Salvarani C , MacchioniP, ManziniCet al.: Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.Ann. Intern Med.146, 631–639(2007).
  • Hoffman GS , CidMC, Rendt-ZagarKEet al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.Ann. Intern Med.146, 621–630(2007).
  • Martinez-Taboada VM , Rodriguez-ValverdeV, CarrenoLet al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.Ann. Rheum. Dis.67, 625–630(2008).
  • Bhatia A , EllPJ, EdwardsJC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis.Ann. Rheum. Dis.64, 1099–1100(2005).
  • Mayrbaeurl B , HinterreiterM, BurgstallerS, WindpesslM, ThalerJ: The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab.Clin. Rheumatol.26, 1597–1598(2007).
  • Brown MM , BrownGC, SharmaS, KistlerJ, BrownH: Utility values associated with blindness in an adult population.Br. J. Ophthalmol.85, 327–331(2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.